보고서 요약(국문)

개요
전 세계 프로피온산혈증 치료제 시장은 2022년 YY억 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
프로피온산혈증은 신체가 단백질과 지질(지방)의 특정 부분을 제대로 처리하지 못하는 유전 질환입니다. 이는 유기산 장애로 분류되며, 유기산이라고 하는 특정 산이 비정상적으로 축적되는 질환입니다.
프로피온산혈증은 프로피오닐-CoA를 메틸 말로닐-CoA로 전환하는 반응을 촉매하는 효소인 프로피오닐-CoA 카르복실라제(PCC)의 결핍으로 발생합니다. 신생아 선별검사에서 프로피온산혈증으로 진단된 신생아는 C3(프로피오닐카르니틴) 수치가 상승되어 있습니다. 증상이 있는 사람이나 신생아 선별검사에서 발견된 사람의 소변 유기산 검사에서 3-하이드록시프로피오네이트 수치가 상승하고 메틸시트르산, 티글릴글리신, 프로피오닐글리신, 젖산이 검출됩니다.
시장 동향: 성장 동인 및 제약 요인
프로피온산혈증 유병률 증가
프로피온산혈증 유병률 증가는 예측 기간 동안 시장 성장을 촉진하는 중요한 요인 중 하나입니다. 예를 들어, NCBI에 발표된 논문에 따르면 미국에서는 약 10만 명당 1명꼴로 프로피온산혈증이 발생합니다.

이 질환은 그린란드의 이누이트족, 일부 아미쉬 공동체, 사우디아라비아인을 포함한 전 세계 여러 인구 집단에서 더 흔하게 나타나는 것으로 보입니다. 또한, 치료법의 발전, 케톤성 고글리신혈증 유병률 증가 등도 예측 기간 동안 시장 성장을 견인할 것입니다.

시장 동향: 제약 요인
프로피온산혈증 시장의 제약 요인 중 하나는 이 선천성 대사 이상 질환의 희귀성, 이질성, 사망률 및 예측 불가능한 결과로 인해 새로운 약물 치료법에 대한 임상 시험을 모집하고 수행하는 것이 매우 복잡하다는 점입니다. 이러한 임상 시험의 임상적 평가 지표를 선정하는 것이 특히 어렵습니다. 따라서 이러한 희귀 질환에 대한 새로운 치료법 연구를 지원할 수 있는 프로피온산혈증의 대체 평가 지표가 될 수 있는 바이오마커를 식별해야 할 필요성이 분명합니다.
세분화 분석
전 세계 프로피온산혈증 치료제 시장은 약물 종류, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
약물 종류 중 L-카르니틴은 시장 점유율의 약 40.2%를 차지했습니다.
L-카르니틴은 예측 기간 동안 시장을 주도할 것으로 예상됩니다. L-카르니틴은 인체의 뇌, 간, 신장에서 생성되는 화학 물질입니다. L-카르니틴은 신체가 지방을 에너지로 전환하는 데 도움을 줍니다. 심장과 뇌 기능, 근육 운동 및 기타 여러 신체 과정에 중요합니다. 신체는 L-카르니틴을 아세틸-L-카르니틴과 프로피오닐-L-카르니틴이라는 다른 화학 물질로 전환할 수 있습니다.
L-카르니틴 치료는 프로피온산혈증 환자 3명과 정상 대조군 3명에서 단쇄 아실카르니틴의 생성 및 배설을 크게 증가시켰습니다. 고속 원자 충격 질량 분석법과 일정한 자기장(B) 대 전기장(E) 비율에서의 연결 스캐닝을 사용하여 프로피온산혈증 환자에서 아실카르니틴이 프로피오닐카르니틴임을 확인했습니다. 정상 어린이들은 주로 아세틸카르니틴을 배설했습니다.

지리적 분석
북미는 2022년 시장 점유율의 약 38.4%를 차지했습니다.
북미는 의료 인프라 개선, FDA 승인, 프로피온산혈증 유병률 증가, 주요 업체와의 협력 및 인수 등으로 인해 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상되며, 이러한 요인들이 예측 기간 동안 북미 지역의 시장 지배력을 강화할 것으로 전망됩니다.
예를 들어, 2022년 5월 미국 식품의약국(FDA)은 미국 국립보건원(NIH) 산하 국립번역과학진흥센터(NCATS)에 프로피오닐-CoA 카르복실라제 알파 소단위(PCCA) 결핍으로 인한 프로피온산혈증 치료를 위한 임상시험 단계의 유전자 치료제인 AAV9-hPCCA(NCATS-BL0746)에 대해 희귀의약품 지정을 승인했습니다.

COVID-19 영향 분석
COVID-19는 프로피온산혈증 시장에 상당한 영향을 미쳤습니다. 프로피온산혈증 환자가 COVID-19에 감염될 경우 대사 기능 부전의 위험이 있을 수 있다는 연구 결과가 있지만, 감염의 임상 경과는 일반적으로 경미하며 심각한 후유증 없이 회복될 수 있습니다.
NCBI에 발표된 또 다른 사례 보고서에서는 프로피온산혈증을 포함한 기저 대사 질환을 가진 두 환자가 COVID-19에 감염된 사례를 설명합니다. 이 보고서는 선천성 대사 이상(IEM)을 가진 개인이 COVID-19 감염 시 대사 기능 부전의 위험에 처할 수 있음을 시사합니다. 그러나 바이러스가 일반적인 경우보다 더 심각한 대사 악화를 유발하는 것으로 보이지는 않습니다.
경쟁 환경
프로피온산혈증 치료제 시장의 주요 글로벌 업체로는 Leadiant, Pfizer, ScotMedcare, Cambridge Healthcare, Teva Pharmaceuticals, Wellona Pharma, Merck, AdvaCare Pharma, Serve Pharmaceuticals, Vitane Pharmaceuticals, Inc 등이 있습니다.

주요 개발 사항
 2023년 5월, 메신저 RNA(mRNA) 치료제 및 백신 개발을 선도하는 생명공학 기업인 모더나(Moderna, Inc.)는 프로피온산혈증(PA) 치료를 위한 임상 1/2상 mRNA 치료제인 mRNA-3927의 중간 데이터 보고 초록이 2023년 5월 16일부터 20일까지 미국 캘리포니아주 로스앤젤레스에서 개최되는 미국 유전자 및 세포 치료 학회(ASGCT) 연례 회의에서 발표될 예정이라고 밝혔습니다.
 2022년 8월, 브리지바이오파마(BridgeBio Pharma)는 프로피온산혈증(PA) 및 메틸말론산혈증(MMA) 치료를 위한 잠재적 최고 효능 치료제인 BBP-671의 임상 1상 시험에서 첫 번째 환자에게 투약을 시작했다고 발표했습니다. BBP-671은 CoA 생합성 경로의 핵심 효소인 판토텐산 키나아제를 알로스테릭하게 조절하여 CoA 수치를 증가시키는 것을 목표로 하는 경구 투여용 치료제입니다.

 2021년 1월, 미국 식품의약국(FDA)은 프로피온산혈증(PA)으로 인한 급성 고암모니아혈증 치료의 보조 요법으로 카르바글루(Carbaglu)의 새로운 적응증을 승인했습니다.
보고서 구매 이유:

• 약물 종류, 투여 경로, 유통 채널 및 지역별로 세분화된 글로벌 프로피온산혈증 치료제 시장을 시각화하고 주요 상업 자산 및 기업을 파악할 수 있습니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴할 수 있습니다.
• 모든 세그먼트를 포함한 프로피온산혈증 치료제 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 기업의 핵심 제품 정보를 담은 엑셀 파일 형태의 제품 맵핑 자료를 제공합니다.

글로벌 프로피온산혈증 치료제 시장 보고서는 약 69개의 표, 70개의 그림, 그리고 185페이지 분량으로 구성됩니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Propionic Acidemia Drugs Market reached US$ YY billion in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.
Propionic acidemia is an inherited disorder in which the body is unable to process certain parts of proteins and lipids (fats) properly. It is classified as an organic acid disorder, which is a condition that leads to an abnormal buildup of particular acids known as organic acids.
Propionic acidemia is caused by a deficiency of propionyl-CoA carboxylase (PCC), the enzyme that catalyzes the conversion of propionyl-CoA to methyl malonyl-CoA. Newborns with PA tested by expanded newborn screening have elevated C3 (propionylcarnitine). Testing of urine organic acids in persons who are symptomatic or those detected by newborn screening reveals elevated 3-hydroxypropionate and the presence of methylcitrate, tiglylglycine, propionylglycine, and lactic acid.
Market Dynamics: Drivers and Restraints
Rise in the prevalence of propionic acidemia
The rise in the prevalence of propionic acidemia is one of the significant factors that helps the market to grow during the forecast period. For instance, according to the article published in NCBI Propionic acidemia affects about 1 in 100,000 people in the United States.
The condition appears to be more common in several populations worldwide, including the inuit population of Greenland, some amish communities, and saudi arabians. Furthermore, the rise in the advancements in treatment options, the rise in the prevalence of ketotic hyperglycinemia and others will also drive the market growth during the forecast period.
Market Dynamics: Restraint
One of the restraint factors of the propionic acidemia market is it is highly complex to enroll and conduct a clinical trial of a new drug treatment for propionic acidemia, due to the rarity, heterogeneity, mortality, and unpredictable outcomes associated with these inborn errors of metabolism. Selecting clinical endpoints for these trials is particularly challenging. Thus, there is a clear need to identify which biomarkers for propionic acidemia could be surrogate endpoints to support the investigation of new therapies for these rare diseases.
Segment Analysis
The global propionic acidemia drugs is segmented based on drug class, route of administration distribution channel and region.
The L-carnitine from the drug class segment accounted for approximately 40.2 % of the market share
The L-carnitine from the drug class segment accounted for 40.2% and it is expected to be dominated during the forecast period. L-carnitine is a chemical that is made in the human brain, liver, and kidneys. It helps the body turn fat into energy. L-carnitine is important for heart and brain function, muscle movement, and many other body processes. The body can convert L-carnitine to other chemicals called acetyl-L-carnitine and propionyl-L-carnitine
Treatment with L-carnitine greatly enhanced the formation and excretion of short-chain acylcarnitines in three patients with propionic acidemia and in three normal controls. The use of fast atom bombardment mass spectrometry and linked scanning at constant magnetic (B) to electric (E) field ratio identified acylcarnitine as propionylcarnitine in patients with propionic acidemia. The normal children excreted mostly acetylcarnitine.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing, to the improved healthcare infrastructure, FDA approvals, rise in the prevalence of propionic acidemia, collaborations and acquisitions with the key players and others expected to dominate by this region during the forecast period.
For instance, in May 2022, the U.S. Food and Drug Administration (FDA) granted the National Institutes of Health (NIH)’s National Center for Advancing Translational Sciences (NCATS) an orphan drug designation for AAV9-hPCCA (NCATS-BL0746), investigational gene therapy for the treatment of propionic acidemia resulting from a deficiency of Propionyl-CoA Carboxylase, alpha subunit (PCCA).
COVID-19 Impact Analysis
Covid 19 had a substantial impact on the propionic acidemia market where evidence suggests that patients with propionic acidemia who contract COVID-19 may be at risk of metabolic decompensation, but the clinical course of the infection is generally mild and recovery is possible without severe clinical consequences.
Another case report published in NCBI it describes those two patients with underlying metabolic disorders, including propionic acidemia, who contracted COVID-19. The report suggests that individuals with an underlying inborn error of metabolism (IEM) are at risk of metabolic decompensation in the setting of a COVID-19 infection. However, the virus does not appear to cause a more severe metabolic deterioration than is typical.
Competitive Landscape
The major global players in the propionic acidemia drugs market include Leadiant, Pfizer, ScotMedcare, Cambridge Healthcare, Teva Pharmaceuticals, Wellona Pharma, Merck, AdvaCare Pharma, serve pharmaceuticals, Vitane Pharmaceuticals, Inc and among others.
Key Developments
 In May 2023, Moderna, Inc, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, stated that an abstract reporting on interim data from the Phase I/II trial of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA) has been accepted for presentation at the 2023 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting being held May 16-20, 2023 in Los Angeles, CA.
 In August 2022, BridgeBio Pharma stated the Dosing of the First Patient in the Phase I Trial of BBP-671, a Potential best-in-class treatment for propionic acidemia (PA) and methylmalonic acidemia (MMA)BBP-671 is an investigational oral therapy intended to increase CoA levels by allosterically modulating pantothenate kinases, key enzymes in the CoA biosynthesis pathway.
 In January 2021, Food and Drug Administration (FDA) approved a new indication for Carbaglu for use as adjunctive therapy in the treatment of acute hyperammonemia due to propionic acidemia (PA).
Why Purchase the Report?
• To visualize the global propionic acidemia drugs market segmentation-based drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of propionic acidemia drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global propionic acidemia drugs market report would provide approximately 69 tables, 70 figures, and 185 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Route of Administration
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Driver
4.1.1.1. Rise in the prevalence of propionic acidemia
4.1.1.2. Advancements in treatment options
4.1.2. Restraints
4.1.2.1. Challenges associated with the drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. L-Carnitine *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Antibiotics
7.4. Other Drug Supplements
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Intravenous
8.4. Intramuscular
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug class
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug class
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug class
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug class
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug class
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Leadiant
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Pfizer
12.3. ScotMedcare
12.4. Cambridge Healthcare
12.5. Teva Pharmaceuticals
12.6. Wellona Pharma
12.7. Merck
12.8. AdvaCare Pharma
12.9. SERVE PHARMACEUTICALS
12.10. Vitane Pharmaceuticals, Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Leadiant, 4. Key Developments, Pfizer, ScotMedcare, Cambridge Healthcare, Teva Pharmaceuticals, Wellona Pharma, Merck, AdvaCare Pharma, SERVE PHARMACEUTICALS, Vitane Pharmaceuticals, Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Propionic Acidemia Drugs Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Propionic Acidemia Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Propionic Acidemia Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Propionic Acidemia Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Propionic Acidemia Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Propionic Acidemia Drugs Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Propionic Acidemia Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 8 Global Propionic Acidemia Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Propionic Acidemia Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 10 Global Propionic Acidemia Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Propionic Acidemia Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 12 Global Propionic Acidemia Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Propionic Acidemia Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 14 Global Propionic Acidemia Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Propionic Acidemia Drugs Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Propionic Acidemia Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 17 North America Propionic Acidemia Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 18 North America Propionic Acidemia Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 19 North America Propionic Acidemia Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 North America Propionic Acidemia Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 21 South America Propionic Acidemia Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 22 South America Propionic Acidemia Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 South America Propionic Acidemia Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 South America Propionic Acidemia Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 25 South America Propionic Acidemia Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 26 Europe Propionic Acidemia Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 27 Europe Propionic Acidemia Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 28 Europe Propionic Acidemia Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 29 Europe Propionic Acidemia Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 30 Europe Propionic Acidemia Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Propionic Acidemia Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Propionic Acidemia Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 33 Asia-Pacific Propionic Acidemia Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Propionic Acidemia Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 35 Asia-Pacific Propionic Acidemia Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Propionic Acidemia Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 37 Middle East & Africa Propionic Acidemia Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 38 Middle East & Africa Propionic Acidemia Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 39 Middle East & Africa Propionic Acidemia Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 40 Leadiant: Overview

Table 41 Leadiant: Product Portfolio

Table 42 Leadiant: Key Developments

Table 43 Pfizer Inc: Overview

Table 44 Pfizer Inc: Product Portfolio

Table 45 Pfizer Inc: Key Developments

Table 46 ScotMedcare: Overview

Table 47 ScotMedcare: Product Portfolio

Table 48 ScotMedcare: Key Developments

Table 49 Cambridge Healthcare: Overview

Table 50 Cambridge Healthcare: Product Portfolio

Table 51 Cambridge Healthcare: Key Developments

Table 52 Teva Pharmaceuticals: Overview

Table 53 Teva Pharmaceuticals: Product Portfolio

Table 54 Teva Pharmaceuticals: Key Developments

Table 55 Wellona Pharma: Overview

Table 56 Wellona Pharma: Product Portfolio

Table 57 Wellona Pharma: Key Developments

Table 58 Merck: Overview

Table 59 Merck: Product Portfolio

Table 60 Merck: Key Developments

Table 61 AdvaCare Pharma: Overview

Table 62 AdvaCare Pharma: Product Portfolio

Table 63 AdvaCare Pharma: Key Developments

Table 64 SERVE PHARMACEUTICALS: Overview

Table 65 SERVE PHARMACEUTICALS: Product Portfolio

Table 66 SERVE PHARMACEUTICALS: Key Developments

Table 67 Vitane Pharmaceuticals, Inc.: Overview

Table 68 Vitane Pharmaceuticals, Inc.: Product Portfolio

Table 69 Vitane Pharmaceuticals, Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 2 Global Propionic Acidemia Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 3 Global Propionic Acidemia Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Propionic Acidemia Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Propionic Acidemia Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 6 Global Propionic Acidemia Drugs Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Propionic Acidemia Drugs Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 8 L-Carnitine Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 9 Antibiotics Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 10 Global Propionic Acidemia Drugs Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 11 Oral Route of Administration in Global Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 12 Intravenous Route of Administration in Global Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 13 Intramuscular Route of Administration in Global Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 14 Global Propionic Acidemia Drugs Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 15 Hospital Pharmacies Distribution Channel in Global Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 16 Retail Pharmacies Distribution Channel in Global Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 17 Online Pharmacies Distribution Channel in Global Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 18 Global Propionic Acidemia Drugs Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 19 0 Distribution Channel in Global Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 20 Global Propionic Acidemia Drugs Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 21 North America Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 22 Asia-Pacific Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 23 Europe Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 24 South America Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 25 Middle East and Africa Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 26 North America Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 27 North America Propionic Acidemia Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 28 North America Propionic Acidemia Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 29 North America Propionic Acidemia Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 30 North America Propionic Acidemia Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 31 North America Propionic Acidemia Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 32 South America Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 33 South America Propionic Acidemia Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 34 South America Propionic Acidemia Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 35 South America Propionic Acidemia Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 36 South America Propionic Acidemia Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 37 South America Propionic Acidemia Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 38 Europe Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 39 Europe Propionic Acidemia Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 40 Europe Propionic Acidemia Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 41 Europe Propionic Acidemia Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 42 Europe Propionic Acidemia Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 43 Europe Propionic Acidemia Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 44 Asia-Pacific Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 45 Asia-Pacific Propionic Acidemia Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 46 Asia-Pacific Propionic Acidemia Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 47 Asia-Pacific Propionic Acidemia Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 48 Asia-Pacific Propionic Acidemia Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 49 Asia-Pacific Propionic Acidemia Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 50 Middle East & Africa Propionic Acidemia Drugs Market Value, 2021-2030 (US$ Million)

Figure 51 Middle East & Africa Propionic Acidemia Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 52 Middle East & Africa Propionic Acidemia Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 53 Middle East & Africa Propionic Acidemia Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 54 Middle East & Africa Propionic Acidemia Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 55 Leadiant: Financials

Figure 56 Pfizer Inc: Financials

Figure 57 ScotMedcare: Financials

Figure 58 Cambridge Healthcare: Financials

Figure 59 Teva Pharmaceuticals: Financials

Figure 60 Wellona Pharma: Financials

Figure 61 Merck: Financials

Figure 62 AdvaCare Pharma: Financials

Figure 63 SERVE PHARMACEUTICALS: Financials

Figure 64 Vitane Pharmaceuticals, Inc.: Financials

세계 프로피온산혈증 치료제 시장 – 2023-2030

Global Propionic Acidemia Drugs Market -2023-2030